Skip to content

GSR and Charlie Lee Lead $100M Investment into MEI, Reveal Institutional LTC Treasury Strategy

2025-07-22 09:06:41

GSR and Charlie Lee Lead $100M Investment into MEI, Reveal Institutional LTC Treasury Strategy

Main Idea

GSR and Litecoin founder Charlie Lee lead a $100M investment into MEI Pharma, aiming to institutionalize Litecoin as a treasury asset and enhance its ecosystem.

Key Points

1. GSR and Charlie Lee are leading a $100M private investment in public equity (PIPE) into Nasdaq-listed MEI Pharma, with participation from the Litecoin Foundation and other firms.

2. The investment is described as a significant step toward institutionalizing Litecoin as a treasury asset, reflecting growing institutional confidence in LTC.

3. Charlie Lee will join MEI's board of directors, and GSR will serve as an execution partner, working closely with MEI and the Litecoin Foundation.

4. MEI Pharma reported $23.7M in cash and no debt as of December 2024, while GSR has been active in supporting blockchain ecosystems, including Polygon-based Katana.

5. Litecoin's price has shown recent gains, trading at $106, up 6.9% in a day and 46% over the past year, though still down 74.1% from its all-time high in May 2021.

Description

GSR , a crypto market maker and trading firm, has announced an investment in and a strategic partnership with the Nasdaq-listed MEI Pharma , marking the first time a public company is aligning its treasury strategy with Litecoin (LTC) at an institutional level, the team says . According to the press release, GSR and Litecoin founder Charlie Lee are lead investors in the $100 million private investment in public equity into the pharmaceutical company. Private investment in public equity ( PIPE ) ...

>> go to origin page

More Reading